In order to provide our clients with a wide range of iPSC characterization services,Creative Bioarray has developed several efficient and reliable methods for iPSC differentiation potential analysis by combining advanced experimental platforms with cutting-edge scientific developments in the field of cell reprogramming. Our professional iPSC characterization services will help our clients optimize their differentiation protocols.
Background
As pluripotent cells, iPSCs have the theoretical ability to produce all cell types found in the body. Several studies have reported the differentiation of human iPSCs into a variety of cell types such as adipocytes, pancreatic β-cells, primitive hematopoietic cells, cardiomyocytes, and several different neuronal cell types. The purity of iPSCs and their potential to differentiate have a direct impact on the productivity and efficiency of cell expansion and the generation of terminally differentiated cell types. Thus after determining that iPSC lines are pluripotent, it is essential to establish that these cells can form tissues from all three germ layers of the embryo. Given that iPSC lines are now widely used in cell-based drug screening, complex disease research, and transplantation therapy, Creative Bioarray has developed several effective and accurate strategies to determine the differentiation potential of these cells prior to their application.
Fig.1 Histological analysis of teratomas formed after transplantation of undifferentiated HES-1 cells. (Gropp, 2012)
Assessing the Differentiation of iPSC Cell Lines
Creative Bioarray has extensive experience in providing iPSC differentiation potential analysis services. We provide predictions of cell differentiation potential many days before cells exhibit a differentiation phenotype to help clients optimize differentiation protocols, particularly for patient-specific iPSC lines through the use of a high-throughput screening procedure.
- Teratoma formation assay
- Embryoid body (EB) formation
- Potential of directed differentiation into specific lineages
Teratoma formation is a fundamental criterion for determining the pluripotency of human iPSCs and assessing their tumorigenic potential based on iPSC formation of teratomas in immunodeficient mice in immunodeficient mice.
Generation of EBs from hiPSCs is an in vitro alternative method for teratoma detection. This method avoids the regulatory issues and substantial costs related to maintaining immunodeficient mice by being performed in vitro using standard tissue culture methods and materials. Moreover, hiPSCs can easily form EBs in multiple ways, which allows for trilineage differentiation and profiling in a more reproducible and controlled manner.
We have developed not only iPSC characterization services, but also a variety of protocols to differentiate iPSC into various lineage-directed cell types to help our customers expand their research, drug discovery or screening programs.
Applications
- Development of human disease models to study pathogenesis and toxicological mechanisms or screening for new drugs.
- Study of normal developmental models for understanding tissue repair and regeneration or screening for potential teratogens.
Advantages
- An innovative research team
- High accuracy and high sensitivity approaches
- Short experimental cycle
As a recognized expert in the field of cell reprogramming, Creative Bioarray is committed to providing the most satisfactory iPSC differentiation potential analysis services to our clients. If you need our technical support, please contact us and we will be glad to provide you with the best service using our innovative technology and extensive experience.
Reference
- Gropp, M.; et al. Standardization of the teratoma assay for analysis of pluripotency of human ES cells and biosafety of their differentiated progeny. Plos One. 2012, 7(9): e45532.